01 1Invega
02 1Invega Sustenna / Xeplion
03 1Invega Sustenna/ Xeplion/ Inveg Trinza/Trevicta
04 5Invega Sustenna/ Xeplion/ Trinza/Trevicta
05 1Invega Sustenna/Xeplion
06 1Invega Sustenna/Xeplion/Trinza/Trevicta
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 3,653
2019 Revenue in Millions : 3,330
Growth (%) : 10
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 4,022
2020 Revenue in Millions : 3,653
Growth (%) : 10
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 4,140
2021 Revenue in Millions : 4,022
Growth (%) : 3
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 4,115
2022 Revenue in Millions : 4,140
Growth (%) : -1
Main Therapeutic Indication : Neuroscience/Mental Health
Currency : USD
2014 Revenue in Millions : 27.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 1,588
2014 Revenue in Millions : 1,830
Growth (%) : 15%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 2,214
2015 Revenue in Millions : 1,830
Growth (%) : 21
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 2,569
2016 Revenue in Millions : 2,214
Growth (%) : 16
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 2,928
2017 Revenue in Millions : 2,569
Growth (%) : 14%
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 3,330
2018 Revenue in Millions : 2,928
Growth (%) : 14
LOOKING FOR A SUPPLIER?
